AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 51 min read$TWST

Cho Dennis sold $91K of TWST

Cho Dennis (See Remarks) sold 1,070 shares of Twist Bioscience Corp (TWST) at $85.32 on 2026-08-03.

Original reporting
SEC EDGAR · Cho Dennis
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosed open-market sale may modestly influence short-term sentiment, but it does not provide new operational, financial, or regulatory information about TWST.

02

Market read

A routine insider sale is disclosed, offering limited incremental trading signal absent other company-specific catalysts.

03

What to watch

The article does not state the insider’s total compensation, tax obligations, or whether other sales occurred around the same time; absence of a cited 10b5-1 plan may increase speculation but is not proof of information advantage.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, sale dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for Twist Bioscience (TWST).

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience officer Cho Dennis filed a Form 4 selling 1,070 shares at $85.3212 on 2026-08-03, totaling $91,293.68.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing discloses a single insider sale size and price, but provides no new company fundamentals, guidance, or legal/operational developments.

Market effects

Sector

Minimal; insider sale does not change biotech/genomics sector fundamentals in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification and do not necessarily signal reduced confidence, especially when the company has no accompanying negative news in the filing.

Key entities

  • issuer
    Twist Bioscience Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Cho Dennis

    Officer who sold 1,070 shares at $85.3212 on 2026-08-03.

Read at source← All news

Related articles

AUG 5
$TWSTMedAI 8/10

Twist Announces Pricing Of $300 Mln Underwritten Upsized Public Offering

Twist Bioscience (TWST) priced an underwritten upsized public offering of 3.12 million shares at $96.00 each, raising about $300 million in gross proceeds. Underwriters received a 30-day option for up to an additional $37.5 million. Proceeds will fund R&D, manufacturing expansion, working capital and general purposes. Closing is expected Aug. 6, 2026.

rttnews.com3 min
AUG 4
$TWSTMed

Twist Bioscience Q3 Earnings Call Highlights

Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.

yahoo.com6 min
AUG 3
$TWSTMed

Why is Twist Bioscience stock sliding today?

Twist Bioscience shares (TWST) fell 4.2% in pre-open after its fiscal Q3 results missed EPS expectations. The company reported an EPS loss of $0.56 versus $0.48 expected, while revenue was $118.4M, above the $114.54M estimate. The miss follows similar EPS shortfalls in prior quarters, with mixed analyst actions noted.

investing.com3 min
AUG 3
$TWSTHigh

Twist Bioscience Corp (TWST): Results of Operations and Financial Condition

Twist Bioscience Corp (TWST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 twst-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results — Record revenue of $118.4 million in 3QFY26 ; Increase of more than 23% over $96.1 million in 3QFY25; 14th consecutive quarter of sequential growth

SEC EDGAR 8-K4 min
MAY 27
$AMDMedAI 8/10

Cathie Wood Pours $8. 5M Into Cerebras Amid Buzz Around AI Chip Upstart, Wont Stop Dumping AMD - Advanced

According to Benzinga, Cathie Wood’s Ark made a $10.8M purchase of Cerebras shares (42,126) on Friday, while also selling 16,998 shares of Teradyne and buying 2,451 shares of Twist Bioscience via ARKK. Separately, the report notes AMD is ramping Vera Rubin production, but U.S.-China policy and China’s share of net sales remain key factors for investors.

benzinga.com4 min